US Patent
US11998605 — Stabilized aqueous compositions of neuromuscular blocking agents
Formulation · Assigned to B Braun Melsungen AG · Expires 2039-07-22 · 13y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a stabilized aqueous composition containing Rocuronium at a concentration of 5-20 mg/mL, with D-gluconic acid or D-glucono-delta-lactone as an excipient.
USPTO Abstract
The present invention relates to an aqueous composition comprising: (i) a steroidal neuromuscular blocking agent that is a Rocuronium salt, further wherein the steroidal neuromuscular blocking agent is present at a concentration ranging from 5 mg/mL to 20 mg/mL based on the total volume of the aqueous composition; and (ii) an excipient that includes D-gluconic acid, D-glucono-delta-lactone, or a combination thereof, where the steroidal neuromuscular blocking agent and the excipient are dissolved in a solution consisting of water. Furthermore the present invention relates to a liquid pharmaceutical composition comprising or consisting of said aqueous composition and a method for producing said aqueous composition.
Drugs covered by this patent
- Rocuronium (Rocuronium Bromide) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.